180 Life Sciences Corp.
ATNF
$1.82
-$0.0099-0.54%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.86% | 10.51% | 16.50% | 36.52% | 32.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.70% | 5.65% | 7.70% | 16.16% | 14.43% |
| Operating Income | 24.70% | -5.65% | -7.70% | -16.16% | -14.43% |
| Income Before Tax | 43.82% | -174.14% | -320.85% | -1,682.61% | -94.95% |
| Income Tax Expenses | -149.22% | -49,713.64% | -7,627.05% | -5,196.07% | -3,963.36% |
| Earnings from Continuing Operations | 48.52% | -153.64% | -316.78% | -1,658.27% | -90.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.52% | -153.64% | -316.78% | -1,658.27% | -90.54% |
| EBIT | 24.70% | -5.65% | -7.70% | -16.16% | -14.43% |
| EBITDA | 24.83% | -5.49% | -7.87% | -16.30% | -14.54% |
| EPS Basic | 81.36% | -68.62% | -257.19% | -819.20% | -22.83% |
| Normalized Basic EPS | -223.65% | -335.76% | -138.20% | -27.52% | 94.89% |
| EPS Diluted | 81.36% | -68.28% | -388.24% | -129.04% | 15.39% |
| Normalized Diluted EPS | -223.55% | -335.79% | -139.08% | -12.25% | 94.99% |
| Average Basic Shares Outstanding | 278.57% | 171.22% | 95.32% | 45.92% | 20.52% |
| Average Diluted Shares Outstanding | 278.48% | 171.15% | 93.85% | 44.79% | 19.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
